Boutique adviser’s work for two former executives has threatened its lucrative ties to the vaccine maker
Once-hyped genetic testing company hit by data breach, plunging share price and board resignations
Proposed sale of controlling stake to US private equity group has sparked backlash in country
Losses widen at Isomorphic Labs, as new Nobel Prize winner pushes forward with effort to use AI in healthcare
Not quickly, anyway
Drug company made claims even though a study of donanemab’s preventive potential is not due to end until 2027
Expiry of Novo Nordisk’s UK patent for Saxenda seen as offering a ‘dry run’ for future generic versions of Ozempic
US private equity group nears deal for pharma spin-off after edging out PAI-led consortium
And valuing the weight-loss drug manufacturers
Plus, the senior bankers at the centre of HSBC’s plans to cut costs and 7-Eleven’s latest tactic to fend of a $47bn hostile takeover
Agreement over heartburn medicine should help to resolve concerns hanging over UK drugmaker
A seemingly misfired message has embroiled Albert Bourla and his company in a high-stakes activist battle
A big market narrative with an eerie absence of sceptics
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain
Hedge fund had enlisted help from ex-chair Ian Read and former finance chief Frank D’Amelio
CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs
Fund run by Jeff Smith builds $1bn stake in vaccine maker and pitches shake-up plan
The drugmaker is worth less now than before the pandemic
Plus, Jane Street comes for Goldman’s trading crown and Byju’s can’t find the money
Ian Read has called his successors about the activist’s ideas for turning round the vaccine maker
Pharma giant’s share price has fallen below pre-pandemic levels after shortlived bump from Covid vaccine
US biotech researches treatments to reduce muscle loss from blockbuster diet medicines
Weight loss drugs appear to be having an effect at the population level
Drugmakers have been targeted on national security grounds and could lose customers if Congress passes Biosecure Act
The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’
